Premium
A T‐cell neoplasia showing clinicopathologic features of malignant histiocytosis with novel chromosomal abnormalities and N‐ ras mutation
Author(s) -
Itoyama Takahiro,
Sadamoriy Naoki,
Sasagawa Ippei,
Nakamura Hideo,
Tokunaga Seiji,
Yamada Yasuaki,
Ichimaru Michito,
Yoshida Takahisa,
Kikuchi Masahiro,
Takeshima Fuminao,
Iwasaki Keisuke,
Asai Sadahiro,
Yamamori Shunji,
Shimizu Shoichi
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910415)67:8<2103::aid-cncr2820670816>3.0.co;2-1
Subject(s) - malignant histiocytosis , pathology , histiocyte , cd30 , mutation , lymphoma , point mutation , cytogenetics , gene rearrangement , histiocytosis , chromosome , anaplastic large cell lymphoma , biology , cancer research , medicine , gene , genetics , disease
Malignant histiocytosis (MH) is a distinct disease entity defined clinically and morphologically. However, the neoplastic origin of MH is not well established. The authors report a 26‐year‐old woman who showed the typical clinicopathologic features of so‐called MH. Cytogenetic and molecular genetic examinations were performed in addition to the morphologic and immunologic approach. The expression of CD2 and T‐cell receptor gene rearrangements indicated the T‐cell origin of this case. CD30, which is positive for anaplastic large cell lymphoma (Ki‐1 lymphoma), was not expressed. The cytogenetic study revealed a clonal chromosome abnormality involving 3q25, 6p21, 11p15, and 11q21. An N‐ ras point mutation within codon 12 (GGT→GCT) was also detected. These findings indicate that MH defined clinically and morphologically is not a tumor of true histiocytic origin and that it should be reclassified on the basis of immunologic, cytogenetic, and molecular genetic data.